The U.S. Food and Drug Administration awarded its first Commissioner’s National Priority Vouchers to psychedelic drug programs on April 24, six days after President Trump’s executive order directing the agency to expedite review of psychedelic therapies for serious mental illness. The vouchers went to three programs: Compass Pathways’ psilocybin (COMP360) for treatment-resistant depression, the Usona Institute’s psilocybin (PSIL201) for major depressive disorder, and Transcend Therapeutics’ methylone (TSND-201) for PTSD. The methylone program is being acquired by Otsuka Pharmaceutical in a $1.225 billion deal.

A fourth action arrived the same week: the FDA cleared DemeRx’s noribogaine, an ibogaine derivative, to begin a U.S. clinical trial for alcohol use disorder. Ibogaine was a specific focus of the executive order.

The voucher program, established by the FDA in summer 2025, compresses the standard 10-to-12 month new drug application review to one or two months for selected programs. Eligibility requires a Breakthrough Therapy designation and that the program meet the criteria of the Commissioner’s program. Those criteria leave substantial discretion to the FDA commissioner.

What the executive order actually did

The April 18 executive order, titled Accelerating Medical Treatments for Serious Mental Illness, directs the FDA Commissioner to provide National Priority Vouchers to psychedelic drugs with Breakthrough Therapy designations that meet the program’s existing criteria. It does not approve any psychedelic drug, does not change scheduling, and does not create enforceable rights for patients or providers.

It does three other things. It directs the FDA and DEA to establish a pathway under the Right to Try Act for eligible patients to access investigational psychedelic therapies, including ibogaine compounds, with associated Schedule I handling authorizations for treating physicians. It allocates $50 million in ARPA-H funding for federal-state collaboration on psychedelic research. And it signals a directional shift in administration policy that the previous White House had, by available accounts, been blocking. One analyst noted that the same priority voucher path appears to have been available in February and was held back at the political level, making the executive order as much a signal about a White House change of position as a new regulatory mechanism.

The three programs, ranked by maturity

The voucher list has an internal logic worth reading carefully. The three programs are at different stages, and the selections tell you what the FDA is willing to accelerate and what it is not.

Compass Pathways’ COMP360 is the most advanced. The company has run two Phase 3 trials in treatment-resistant depression. COMP005 read out in June 2025 and COMP006 read out in February 2026, both hitting their primary endpoints with statistically significant separation from placebo. Compass announced on April 24 that the FDA had granted its request for a rolling NDA submission and review in addition to the voucher. The company is targeting NDA submission in Q4 2026.

Usona Institute is a nonprofit running a Phase 3 trial of synthetic psilocybin in major depressive disorder, distinct from Compass’s treatment-resistant focus. Usona received Breakthrough Therapy designation in 2019. Its commercial posture is less developed than Compass’s; the organization does not appear to have a standing commercial team. If the program reaches approval on the accelerated timeline, Usona will likely need a partner to launch.

Transcend Therapeutics’ methylone (TSND-201) is the least mature of the three. It is entering Phase 3, with Phase 2 results in PTSD published in JAMA Psychiatry in February 2026. The program is being acquired by Otsuka Pharmaceutical, the Japanese pharma giant that already markets aripiprazole. The voucher attaches to Otsuka post-close.

The Compass selection was widely anticipated. The Usona selection was anticipated by analysts familiar with the program’s regulatory history. The Otsuka/Transcend selection was the surprise, and the surprise is meaningful.

The Resilient absence is the story

Before the April 24 announcement, the consensus prediction within the psychedelics community had been that the third voucher would go to Resilient Pharmaceuticals, the company formerly known as Lykos Therapeutics, formerly known as MAPS Public Benefit Corporation, for its MDMA program in PTSD. The company has the most clinical-trial history of any psychedelic developer; the indication (PTSD) is the same one the voucher went to; and the field’s chatter had reportedly signaled administration support for the program.

The FDA did not award the voucher to Resilient. Instead, the PTSD voucher went to a Phase 3-entry methylone program. Younger, less proven, but with a cleaner methodological profile.

The reason is sitting in the public record. On September 4, 2025, the FDA released a redacted copy of the Complete Response Letter it had issued to Lykos in August 2024, as part of a broader release of 89 previously unpublished CRLs. The letter is now public reading. It documents instructions given to trial sites not to record certain euphoria-like effects as adverse events; concerns about the reliability of safety reporting across the program; the lack of long-term efficacy data; and the influence of prior MDMA use among participants on the trial’s results. The CRL also questions whether the treatment’s benefits were durable enough to justify approval, noting that while the Phase 3 trials showed statistically significant improvements during the treatment period, long-term follow-up data was insufficient.

Lykos reduced its workforce by approximately 75%, about 75 of roughly 100 employees, in August 2024, immediately following the rejection. Founder Rick Doblin departed the board the same week. CEO Amy Emerson stepped down in September 2024. In August 2025, the company renamed itself Resilient Pharmaceuticals. It has not, by available reporting, launched a new Phase 3 study since the rejection.

The voucher decision reads, in this context, as a clarifying signal: the executive order accelerates programs the agency already considers methodologically defensible. It does not retroactively repair programs the agency has documented concerns about.

What changed for sponsors, and what didn’t

Companies awarded vouchers gain enhanced communications with the FDA and a one-to-two-month review window after NDA filing. They do not gain reduced evidentiary standards. The FDA’s announcement, and the public statements of all three voucher recipients, emphasized this distinction repeatedly. Compass CEO Kabir Nath stated that “while the CNPV may provide process efficiencies and accelerated review timelines, an NDA submission must still meet FDA’s established standards of clinical evidence, scientific rigor, and regulatory compliance.” Usona’s statement framed the voucher as accelerating review “to approximately one to two months” while explicitly noting “it does not alter scientific or regulatory standards.”

For sponsors not on the voucher list, the executive order’s effect is more diffuse. The $50 million ARPA-H allocation requires state matching and applies to research funding rather than commercial approval. The Right to Try expansion creates a pathway for individual patient access but does not constitute commercial approval. Sponsors whose programs are pre-Breakthrough or pre-Phase 3 will see no direct regulatory acceleration from the order itself.

The FDA also indicated on April 24 that final guidance for sponsors developing psychedelic drugs would be released “imminently,” meaning finalization of the draft guidance the agency first published in June 2023. The 2023 draft document remains the operative framework. Its finalization, when it arrives, is the regulatory document that will actually structure how Phase 3 programs are designed going forward, more so than the executive order or the voucher program.

Market response

The voucher announcement and the executive order produced an immediate market response in publicly traded psychedelic equities. Compass’s share price moved from approximately $6.66 in early April to a high of $9.92 following the order. Other names in the sector, including GH Research, Definium (formerly MindMed), and AtaiBeckley, recorded smaller increases. The two nonprofit programs (Usona, and the privately-held Transcend ahead of close) are not directly investable.

The polymarket prediction market for “FDA approves a psychedelic for medical use in 2026” moved from approximately 18% the day before the order to roughly 68% after the announcements, a measure of how dramatically the market’s read on the Compass approval timeline shifted.

For Resilient, no public equity exists; the company is privately held by MAPS. Its strategic position is harder to read from public information, but the absence of a voucher, the absence of a launched additional Phase 3 trial, and the public release of the CRL together describe a program that the agency has not been persuaded to reconsider on the timeline the executive order created.

What to watch next

Three near-term inflection points define the rest of 2026. First: Compass’s NDA submission, targeted for Q4 2026, and whether the rolling review allows that timeline to slip earlier. With the voucher’s one-to-two-month review window, a Q4 submission could plausibly produce an FDA decision in late 2026 or early 2027, which would make COMP360 the first classic psychedelic ever approved by the FDA.

Second: the imminent finalization of the FDA’s 2023 draft guidance on psychedelic clinical trials. The document will likely be the methodological reference for every Phase 3 program designed after this year, and its handling of blinding, expectancy controls, dose-response design, and safety monitoring will determine which programs the agency considers approvable on what timelines.

Third: the Resilient program’s path back to the FDA. The company has stated its intent to engage with the agency on resubmission, but has not yet launched the additional Phase 3 trial the original CRL requested. Whether it does, and how the trial is designed, will determine whether MDMA-assisted therapy has a credible path to approval in the second half of this decade or is structurally finished as a near-term commercial program.

The executive order changed the political ground under all three of those questions. It did not change the methodological ones. Sponsors who read the order as the latter are misreading it.